Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation

Table 4

Multivariate analysis of factors associated with transplant outcomes.

	HR	95% CI	value
Prolonged isolated; thrombocytopenia
Infused CD34+ cells ≥ median	0.481	0.232–1.001	0.050
DSA
MFI ≥ 1000	3.262	1.339–7.946	0.009
TRM
Disease status	1.753	(0.985–3.118)	0.056
Infused CD4+ cells ≥ median	1.899	(1.079–3.340)	0.026
DSA
MFI ≥ 1000	2.320	(1.169–4.426)	0.044
Relapse
Disease status	3.882	(2.103–7.166)	<0.001
HLA-DP	2.552	(1.139–5.742)	0.0230
DFS
Disease status	2.667	(1.761–4.038)	<0.001
cGVHD	0.622	(0.423–0.916)	<0.016
OS
Disease status	2.504	(1.643–3.817)	<0.001
cGVHD	0.612	(0.413–0.908)	0.015
DSA
MFI ≥ 1000	1.220	(0.998–2.138)	0.082